Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy,
Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study.
Oncology Nurse Practice: Exemplars in Assuring Safety in Clinical Implementation of Treatment Innovations in Melanoma
The immunotherapeutic landscape is dynamic and rapidly evolving. Immunomodulating therapies have proved effective in enhancing overall patient survival and inducing highly durable tumor responses. In this exciting and rapidly progressing setting, there is significant need for biosafety procedures to prevent unacceptable exposures.
Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy.
The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Results 1 - 6 of 6